|
MaxCyte Inc on Wednesday said it signed a strategic platform licence with biotechnology company Catamaran Bio Inc.
MaxCyte, the US commercial cell-engineering company with an office in Cheshire, England, said the platform licence was to support Catamaran Bio’s CAR-NK cell therapy programmes, allowing it to use MaxCyte’s Flow Electroporation technology and ExPERT platform.
ExPERT delivers essential high-end performance for enabling the next wave of biological and cellular therapeutics, according to MaxCyte.
It will receive platform licensing fees and programme-related revenue in exchange.
‘At MaxCyte, we are passionate about driving the discovery, development and manufacturing of next-generation, cell-based medicines to tackle complex diseases and cancer,’ said Doug Doerfler, chief executive officer at MaxCyte. ‘We are excited to support Catamaran with the advancement of their pipeline of differentiated CAR-NK cell therapies into and through the clinic.’
Catamaran Bio’s business model focuses on developing novel, off-the-shelf chimeric antigen receptor CAR-NK cell therapies to treat a broad range of cancers, particularly involving solid tumours.
The licence is alongside having developed its integrated suite of technologies platform Tailwind to engineer, expand and process NK cells into safe and effective cell therapy products for multiple cancer types.
Shares in MaxCyte were up 1.3% to 443.00 pence each in London on Wednesday morning.
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
